Articles related to NON-HODGKIN LYMPHOMA (NHL)

The recent study on MCL reveals a promising approach in identifying high-risk patients through the combination of MIPI-c and p53 overexpression. This method may guide the development of targeted therapies and personalized treatment plans, addressing the unmet needs of those at the highest risk.

The phase 3 trial findings underscore the potential of axi-cel as a robust second-line treatment for early relapsed or refractory large B-cell lymphoma, providing promising strides in improving patient survival rates.

Explore how the recent FDA approval of Epkinly is poised to transform the therapeutic landscape for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma.

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor at the University of Sydney in Concord, New South Wales, Australia, and head of the Hematology Department at Concord Repatriation General Hospital, provides background on mantle cell lymphoma, its unique treatment challenges, and the significance of the SHINE trial, which assessed ibrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma.

CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.

In a single-center study of 240 patients with lymphoid malignancies — 181 with CLL, 21 with WM, and 38 with other non-Hodgkin lymphomas (NHLs) – patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine compared to the Pfizer-BioNTech vaccine. This superior response was demonstrated in both treatment naïve and treated CLL populations in the study.